Barshatskyi Artur, Vicha Marek, Klementova Olga, Zapletalova Jana, Zuscik Ondrej, Santavy Petr, Juchelka Jan, Konecny Jakub, Simek Martin
University Hospital Olomouc, Olomouc, Czech Republic.
Palacky University Olomouc, Olomouc, Czech Republic.
Kardiochir Torakochirurgia Pol. 2025 Mar;22(1):8-13. doi: 10.5114/kitp.2025.148563. Epub 2025 Mar 17.
Extracorporeal membrane oxygenation (ECMO) is a rescue method in the treatment of severe cardiac or respiratory failure in patients with various etiological factors contributing to this failure and of different ages. The question of ECMO support for patients has recently arisen more frequently, due to the expansion of indications for this method and an increase in the number of patients with severe cardiac or respiratory failures.
To present a single center's 10-year experience with ECMO support, outcomes and mortality.
A retrospective single-center study was conducted on patients with VA-ECMO for cardiac and/or respiratory indications. In this retrospective study, the treatment outcomes of patients undergoing VA-ECMO over a 10-year period within one ECMO center were analyzed, focusing on hospitalization mortality (mid-term outcomes). Additionally, the structure of treated patients was analyzed secondarily according to age, gender, and length of hospitalization.
Out of 114 patients treated with VA-ECMO, 34.2% survived for 30 days, 28.1% survived for 90 days, and 26.3% survived for 12 months. The median age of the patients was 58 years. The median duration of cardiopulmonary support was 2.6 days and duration of hospitalization after support explantation was 2.5 days. There was no significant difference between men and women in terms of age, length of hospitalization, hospitalization mortality, and survival at 30 days, 90 days, and 12 months.
The use of VA-ECMO support in patients with severe to critical cardiopulmonary failure is a commonly employed method in many centers. Data analysis reveals high hospitalization mortality. No predictive factors for short-term and medium-term survival were identified among patient age, gender, duration of support, and length of hospitalization after VA-ECMO support explantation.
体外膜肺氧合（ECMO）是一种用于治疗由多种病因导致严重心脏或呼吸衰竭的不同年龄段患者的抢救方法。由于该方法适应症的扩大以及严重心脏或呼吸衰竭患者数量的增加，ECMO对患者支持治疗的问题最近出现得更为频繁。
介绍一个单中心10年ECMO支持治疗的经验、结果及死亡率。
对因心脏和/或呼吸适应症接受VA-ECMO治疗的患者进行回顾性单中心研究。在这项回顾性研究中，分析了一个ECMO中心10年内接受VA-ECMO治疗患者的治疗结果，重点关注住院死亡率（中期结果）。此外，还根据年龄、性别和住院时间对接受治疗患者的结构进行了二次分析。
在114例接受VA-ECMO治疗的患者中，34.2%存活30天，28.1%存活90天，26.3%存活12个月。患者的中位年龄为58岁。心肺支持的中位持续时间为2.6天，支持撤除后的住院时间为2.5天。在年龄、住院时间、住院死亡率以及30天、90天和12个月生存率方面，男性和女性之间无显著差异。
在严重至危急心肺衰竭患者中使用VA-ECMO支持是许多中心常用的方法。数据分析显示住院死亡率较高。在患者年龄、性别、支持持续时间以及VA-ECMO支持撤除后的住院时间方面，未发现短期和中期生存的预测因素。
